본문 바로가기
KERD
논문KCI 등재

주요우울증에서 아드레날린 알파 2 수용체 유전자 다형성과 Mirtazapine 치료반응의 연관성에 대한 연관연구

An Association Study between Various Adrenergic Alpha 2 Receptor Polymorphisms and Treatment Response to Mirtazapine in Major Depression

김수연|김도관|이유진|정재원|송지혜|명우재|김진우|임신원|최홍
대한노인정신의학회 (Korean Association For Geriatric Psychiatry)|2010.06|노인정신의학 (Journal of Korean Geriatric Psychiatry)|제14권 제1호|pp. 20-26

1

조회

0

다운로드

0

인용

0

참고문헌

초록

Objectives：Genetic differences may contribute to the inter-individual differences in treatment response to antidepressants among patients suffering from major depression. This study investigated a possible association of treatment response to mirtazapine with various adrenergic alpha 2 receptor polymorphisms in major depressive patients. Methods：A 6-week naturalistic treatment study with a blinded outcome examined 84 Korean patients with major depression. Treatment response to mirtazapine was defined as ≥50% decrease in HAM-D scores at six weeks. In this study, four genetic polymorphisms were selected；ADRA2A MspI, ADRA2A DraI, α2BDel301-303, andα2CDel322-325. Results：The Del/Del genotype of α2CDel322-325 exhibited a significant association with response to mirtazapine through multiple logistic regression. ADRA2A DraI, α2BDel301-303, and α2CDel322-325 did not showed a significant association with response to mirtazapine. Conclusion：Based on the finding that α2CDel322-325 polymorphism had an association with the mirtazapine response, we postulate that the polymorphism related to the mechanism of the antidepressant effect is important in predicting the response to antidepressants.

Abstract

Objectives：Genetic differences may contribute to the inter-individual differences in treatment response to antidepressants among patients suffering from major depression. This study investigated a possible association of treatment response to mirtazapine with various adrenergic alpha 2 receptor polymorphisms in major depressive patients. Methods：A 6-week naturalistic treatment study with a blinded outcome examined 84 Korean patients with major depression. Treatment response to mirtazapine was defined as ≥50% decrease in HAM-D scores at six weeks. In this study, four genetic polymorphisms were selected；ADRA2A MspI, ADRA2A DraI, α2BDel301-303, andα2CDel322-325. Results：The Del/Del genotype of α2CDel322-325 exhibited a significant association with response to mirtazapine through multiple logistic regression. ADRA2A DraI, α2BDel301-303, and α2CDel322-325 did not showed a significant association with response to mirtazapine. Conclusion：Based on the finding that α2CDel322-325 polymorphism had an association with the mirtazapine response, we postulate that the polymorphism related to the mechanism of the antidepressant effect is important in predicting the response to antidepressants.

참고문헌 (42)

  1. Souery D, "Treatment-resistant depression", J Clin Psychiatry, 67(Suppl 6), pp.16~22 (2006)
  2. Binder EB, "Pharmacogenomics and antidepressant drugs", Ann Med, 38, pp.82~94 (2006)
  3. Arias B, "5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study", J Clin Psychopharmacol, 23, pp.563~567 (2003)
  4. Pollock BG, "Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression", Neuropsychopharmacology, 23, pp.587~590 (2000)
  5. Rausch JL, "Initial conditions of serotonin transporter kinetics and genotype:influence on SSRI treatment trial outcome", Biol Psychiatry, 51, pp.723~732 (2002)
  6. Smeraldi E, "Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine", Mol Psychiatry, 3, pp.508~511 (1998)
  7. Zanardi R, "Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression", Biol Psychiatry, 50, pp.323~330 (2001)
  8. Kim DK, "Serotonin transporter gene polymorphism and antidepressant response", Neuroreport, 11, pp.215~219 (2000)
  9. Kim H, "Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression", JAMA, 296, pp.1609~1618 (2006)
  10. Yoshida K, "Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients", Prog Neuropsychopharmacol Biol Psychiatry, 26, pp.383~386 (2002)
  11. Cusin C, "Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity", Int J Neuropsychopharmacol, 5, pp.27~35 (2002)
  12. Kirchheiner J, "A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment", Pharmacogenomics J, 7, pp.48~55 (2007)
  13. Szegedi A, "The catechol-O-methyltransferase Val108", 158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression, 2005, pp.5, 49~53
  14. Tadic A, "The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression", Am J Med Genet B Neuropsychiatr Genet, 144B, pp.325~331 (2007)
  15. Tadic A, "A monoamine oxidase B gene variant and short-term antidepressant treatment response", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.1370~1377 (2007)
  16. Tsai SJ, "Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response", Am J Med Genet B Neuropsychiatr Genet, 123B, pp.19~22 (2003)
  17. Yoshida K, "Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms", Am J Psychiatry, 161, pp.1575~1580 (2004)
  18. Yoshida K, "Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder", Prog Neuropsychopharmacol Biol Psychiatry, 26, pp.1279~1283 (2002)
  19. Fawcett J, "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression", J Affect Disord, 51, pp.267~285 (1998)
  20. Kent JM, "SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression", Lancet, 355, pp.911~918 (2000)
  21. Bylund DB, "International Union of Pharmacology nomenclature of adrenoceptors", Pharmacol Rev, 46, pp.121~136 (1994)
  22. Lorenz W, "Expression of three alpha 2-adrenergic receptor subtypes in rat tissues: implications for alpha 2 receptor classification", Mol Pharmacol, 38, pp.599~603 (1990)
  23. Lario S, "MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene", Clin Genet, 51, pp.129~130 (1997)
  24. Small KM, "Complex haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversify receptor expression", Proc Natl Acad Sci USA, 103, pp.5472~5477 (2006)
  25. Fukutake M, "Association of alpha2A-adrenergic receptor gene polymorphism with susceptibility to suicide in Japanese females", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1428~1433 (2008)
  26. Deupree JD, "Possible involvement of alpha-2A adrenergic receptors in attention deficit hyperactivity disorder: radioligand binding and polymorphism studies", Am J Med Genet B Neuropsychiatr Genet, 141B, pp.877~884 (2006)
  27. Park YM, "Weight gain associated with the alpha2a-adrenergic receptor-1,291 C", G polymorphism and olanzapine treatment, 2006, pp.141B, 394~397
  28. Sequeira A, "Alpha 2A adrenergic receptor gene and suicide", Psychiatry Res, 125, pp.87~93 (2004)
  29. Wakeno M, "The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran", J Clin Psychopharmacol, 28, pp.518~524 (2008)
  30. Cho SC, "Possible association of the alpha-2A-adrenergic receptor gene with response time variability in attention deficit hyperactivity disorder", Am J Med Genet B Neuropsychiatr Genet, 147B, pp.957~963 (2008)
  31. Lee HY, "Association of the adrenergic alpha 2a receptor--1291C", G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder, 2009, pp.1262, 1~6
  32. Sykiotis GP, "The alpha2B adrenergic receptor deletion", insertion polymorphism in morbid obesity, 2003, pp.13, 203~207
  33. Laukkanen JA, "Insertion", deletion polymorphism in alpha2-adrenergic receptor gene is a genetic risk factor for sudden cardiac death, 2009, pp.158, 615~621
  34. Saltamavros AD, "alpha 2 beta adrenoreceptor 301-303 deletion polymorphism in polycystic ovary syndrome", Clin Auton Res, 17, pp.112~114 (2007)
  35. Siitonen N, "Association between a deletion", insertion polymorphism in the alpha2B-adrenergic receptor gene and insulin secretion and Type 2 diabetes. The Finnish Diabetes Prevention Study, 2004, pp.47, 1416~1424
  36. Neumeister A, "Effects of a alpha 2C-adrenoreceptor gene polymorphism on neural responses to facial expressions in depression", Neuropsychopharmacology, 31, pp.1750~1756 (2006)
  37. Neumeister A, "Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans", Pharmacogenet Genomics, 15, pp.143~149 (2005)
  38. Kang EH, "Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial", Psychiatry Res, 169, pp.118~123 (2009)
  39. 최홍, "주요우울증에서 단가아민 전달체 유전자 다형성과 Mirtazapine 치료 반응의 연관성에 대한 연구", 대한정신약물학회지, 19(5), pp.266~275 (2008), 대한정신약물학회
  40. Maestu J, "Human adrenergic alpha 2A receptor C-1291G polymorphism leads to higher consumption of sweet food products", Mol Psychiatry, 12, pp.520~521 (2007)
  41. Park L, "Association and linkage of alpha-2A adrenergic receptor gene polymorphisms with childhood ADHD", Mol Psychiatry, 10, pp.572~580 (2005)
  42. Rothman KJ, "No adjustments are needed for multiple comparisons", Epidemiology, 1, pp.43~46 (1990)

관련 논문AI추천

R347C Polymorphisms in ADRA1A Genes and Mirtazapine Treatment Response in Koreans with Major Depression구자현, 원은수, 이민수, 함병주대한생물정신의학회 · 생물정신의학2015 · 제22권 제4호Association between the Alu Insertion/Deletion Polymorphism in the Tissue-Type Plasminogen Activator Gene and Mirtazapine Response in Koreans with Major Depression김다슬, 원은수, 이민수, 장헌수, 함병주대한생물정신의학회 · 생물정신의학2016 · 제23권 제4호한국인 주요우울증 환자에서의 세로토닌 5A 수용체의 유전자 다형성 및 citalopram 치료반응과의 관련성강이헌, 백종우, 심진현, 오정웅, 이민수, 이화영대한생물정신의학회 · 생물정신의학2008 · 제15권 제4호주요우울증 환자에서 세로토닌 6 (5-HT6) 수용체 C267T 다형성과 citalopram 치료반응에 대한 연구강이헌, 오강섭, 이민수, 임세원, 한상우대한생물정신의학회 · 생물정신의학2007 · 제14권 제4호주의력결핍과잉행동장애에서 Alpha-2A-Adrenergic 수용체 유전자와 Methylphenidate 반응과의 연관성에 대한 연구김붕년, 김재원, 김효진, 박민현, 박은진, 박진우, 신민섭, 조수철, 홍순범대한신경정신의학회 · 신경정신의학2011 · 제50권 제5호Pharmacogenomic Study of Patients with Depression김도관, 임신원, Hyeran Kim대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2008 · 제6권 제1호

이 간행물의 다른 논문 (8건)

노인학대박인수, 김신겸pp. 3-8치매 환자에서의 부적절한 성행동이동현, 김경미pp. 9-14노인과 운전장성만pp. 15-19치매 선별용 간이정신상태검사(Mini-Mental State Examination for Dementia Screening；MMSE-DS)와 단축형 MMSE-DS(SMMSE-DS)의 한국 노인 정상규준 연구김태희, 김기웅, 추일한, 윤종철, 유승호, 주진형, 박준혁, 김정란, 김문두, 문석우, 이석범, 도연자, 이동우, 한지원pp. 27-37항우울제 치료 반응의 예측인자로서의 CREB-Phosphorylation이유진, 임신원, 명우재, 송지혜, 정재원, 김도관, 김수연, 김진우pp. 38-43
원문 보기